---
layout: page
title: Publications
subtitle: 
---

# Accepted papers

1. Bardia, A., Chandarlapaty, S., Linden, H. M., Ulaner, G. A., Gosselin, A., Cartot-Cotton, S., Cohen, P., Doroumian, S., **Paux, G.**, Celanovic, M., Pelekanou, V., Ming, J. E., Ternès, N., Bouaboula, M., Lee, J. S., Bauchet, A.-L., & Campone, M. (2022). [AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.]([AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer | Nature Communications](https://doi.org/10.1038/s41467-022-31668-8)) In Nature Communications (Vol. 13, Issue 1). Springer Science and Business Media LLC.
2. Tolaney, S. M., Chan, A., Petrakova, K., Delaloge, S., Campone, M., Iwata, H., Peddi, P. F., Kaufman, P. A., De Kermadec, E., Liu, Q., Cohen, P., **Paux, G.**, Wang, L., Ternès, N., Boitier, E., & Im, S.-A. (2023). [AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer]([AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer | Journal of Clinical Oncology](https://doi.org/10.1200/jco.22.02746)). In Journal of Clinical Oncology (Vol. 41, Issue 24, pp. 4014–4024). American Society of Clinical Oncology (ASCO).
3. Balazard, F., Bertaut, A., Bordet, É., Mulard, S., Blanc, J., Briot, N., **Paux, G.**, Dhaini Merimeche, A., Rigal, O., Coutant, C., Fournier, M., Jouannaud, C., Soulie, P., Lerebours, F., Cottu, P.-H., Tredan, O., Vanlemmens, L., Levy, C., Mouret-Reynier, M.-A., … Pistilli, B. (2023). [Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation]([Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation | JNCI: Journal of the National Cancer Institute | Oxford Academic](https://doi.org/10.1093/jnci/djad109)). In JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP).

# Proceedings abstracts

1. Cao, J., Li, J., Ji, D., Shen, W., Jiang, L., Ma, X., Pang, J., Kanehisa, A., Legrand, F., Pallis, A., **Paux, G.**, Robert, R., Chen, X., Letecheur, P., Qiang, L., & Ding, J. (2015). [126O A phase I study evaluating the safety, efficacy, pharmacokinetics and pharmacodynamics of AL3810 in advanced solid tumors]([Redirecting](https://doi.org/10.1093/annonc/mdv521.02)). In Annals of Oncology (Vol. 26, p. ix37). Elsevier BV. 
2. Le Gouill, S., Wermke, M., Morschhauser, F., Lim, S. T., Salles, G., Kloos, I., de Burgat, V., Becquart, M., **Paux, G.**, Kraus-Berthier, L., Pennaforte, S., Stilgenbauer, S., Walewski, J., & Ribrag, V. (2017). [A NEW BCL-2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST-IN-HUMAN STUDY]([A NEW BCL‐2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST‐IN‐HUMAN STUDY - Le Gouill - 2017 - Hematological Oncology - Wiley Online Library](https://doi.org/10.1002/hon.2437_30)). In Hematological Oncology (Vol. 35, pp. 47–48). Wiley.
3. Campone, M., Bachelot, T., Penault-Llorca, F., Pallis, A., Agrapart, V., Pierrat, M.-J., Poirot, C., **Paux, G.**, Dubois, F., Xuereb, L., Robert, R., & Andre, F. (2018). [Abstract P1-09-11: A phase Ib study of oral administration of lucitanib in combination with fulvestrant in patients with HR+ metastatic breast cancer (mBC)](https://doi.org/10.1158/1538-7445.sabcs17-p1-09-11). In Cancer Research (Vol. 78, Issue 4_Supplement, pp. P1-09-11-P1-09–11). American Association for Cancer Research (AACR). 
4. Orlowski, R. Z., Goldschmidt, H., Cavo, M., Martin, T. G., **Paux, G.**, Oprea, C., & Facon, T. (2018). [Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM)]([Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM). | Journal of Clinical Oncology](https://doi.org/10.1200/jco.2018.36.15_suppl.tps8055)). In Journal of Clinical Oncology (Vol. 36, Issue 15_suppl, pp. TPS8055–TPS8055). American Society of Clinical Oncology (ASCO). 
5. Chandarlapaty, S., Linden, H. M., Neven, P., Petrakova, K., Bardia, A., Kabos, P., Braga, S. A. D. S., Boni, V., Gosselin, A., Cartot-Cotton, S., Doroumian, S., Celanovic, M., Cohen, P., **Paux, G.**, & Campone, M. (2021). [AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC)]([AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). | Journal of Clinical Oncology](https://doi.org/10.1200/jco.2021.39.15_suppl.1058)). In Journal of Clinical Oncology (Vol. 39, Issue 15_suppl, pp. 1058–1058). American Society of Clinical Oncology (ASCO). 
6. Chandarlapaty, S., Linden, H. M., Neven, P., Petrakova, K., Bardia, A., Kabos, P., Braga, S., Boni, V., Pelekanou, V., Ternès, N., Gosselin, A., Celanovic, M., Cohen, P., **Paux, G.**, & Campone, M. (2021). [264P AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC)]([Redirecting](https://doi.org/10.1016/j.annonc.2021.08.547)). In Annals of Oncology (Vol. 32, pp. S476–S477). Elsevier BV. 
7. Chandarlapaty, S., Linden, H. M., Neven, P., Petrakova, K., Bardia, A., Kabos, P., Braga, S., Boni, V., Gosselin, A., Celanovic, M., Cohen, P., **Paux, G.**, Pelekanou, V., Ternès, N., Lee, J. S., & Campone, M. (2022). [Abstract P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer]([Abstract P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer | Cancer Research | American Association for Cancer Research](https://doi.org/10.1158/1538-7445.sabcs21-p1-17-11)). In Cancer Research (Vol. 82, Issue 4_Supplement, pp. P1-17-11-P1-17–11). American Association for Cancer Research (AACR). 
8. Balazard, F., Bertaut, A., Bordet, É., Mulard, S., Blanc, J., Briot, N., Paux, G., Merimeche, A. D., Rigal, O., Coutant, C., Fournier, M., Jouannaud, C., Soulie, P., Lerebours, F., Cottu, P.-H., Tredan, O., Vanlemmens, L., Levy, C., Mouret-Reynier, M.-A., … Pistilli, B. (2022). [Abstract P1-13-08: Patterns of adjuvant endocrine therapy, discontinuations, toxicities and quality of life: Development of a model for early discontinuation using the CANTO cohort](https://doi.org/10.1158/1538-7445.sabcs21-p1-13-08). In Cancer Research (Vol. 82, Issue 4_Supplement, pp. P1-13-08-P1-13–08). American Association for Cancer Research (AACR). 
9. Rossi, G., Brain, E., Dueck, A., De Swert, H., Marreaud, S. I., Partridge, A., Herold, C., Vachon, H., Spanic, T., Arahmani, A., Verbiest, T., Wang, L., Goulioti, T., Malanda, B., Carey, L. A., Anneheim, S., **Paux, G.**, Poncet, C., Metzger, O., & Cameron, D. (2022). [90TiP Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6)]([Redirecting](https://doi.org/10.1016/j.annonc.2022.03.105)). In Annals of Oncology (Vol. 33, pp. S162–S163). Elsevier BV. 
10. Meyskens, T., Metzger, O., Poncet, C., Goulioti, T., Xenophontos, E., Carey, L. A., Wang, L., Rossi, G., Gilham, L., De Swert, H., Casas-Martin, J., Attieh, E., Arahmani, A., De Meulemeester, L., Partridge, A. H., Herold, C. I., **Paux, G.**, Dueck, A. C., Brain, E., & Cameron, D. A. (2022). [Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6)]([Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6). | Journal of Clinical Oncology](https://doi.org/10.1200/jco.2022.40.16_suppl.tps607)). In Journal of Clinical Oncology (Vol. 40, Issue 16_suppl, pp. TPS607–TPS607). American Society of Clinical Oncology (ASCO). 
11. Tolaney, S. M., Chan, A., Petrakova, K., Delaloge, S., Campone, M., Iwata, H., Peddi, P., Kaufman, P. A., de Kermadec, E., Liu, Q., Cohen, P., **Paux, G.**, & Im, S.-A. (2022). [212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)]([Redirecting](https://doi.org/10.1016/j.annonc.2022.07.251)). In Annals of Oncology (Vol. 33, pp. S634–S635). Elsevier BV. 
12. Metzger, O., Herold, C., Poncet, C., De Swert, H., Casas-Martin, J., Partridge, A., Guita, S., Carey, L., Schumacher, E., Goulioti, T., Meyskens, T., Gannon, J., Benlhassan, K., Rossi, G., Xenophontos, E., Arahmani, A., Dueck, A. C., **Paux, G.**, Brain, E., & Cameron, D. A. (2023). [Abstract OT1-04-01: AMEERA-6: Phase 3 Study of Adjuvant Amcenestrant Versus Tamoxifen for Patients With Hormone Receptor-Positive Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity](https://doi.org/10.1158/1538-7445.sabcs22-ot1-04-01). In Cancer Research (Vol. 83, Issue 5_Supplement, pp. OT1-04-01-OT1-04–01). American Association for Cancer Research (AACR). 
